Ethyl 2-(4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylate CAS 161797-99-5 Febuxostat Purity Intermediate > 99.0% Factory
Ruifu Chemical Supply Febuxostat Navberên Têkildar:
Febuxostat CAS 144060-53-7
Ethyl 2-Chloroacetoacetate CAS 609-15-4
4-Hydroxythiobenzamide CAS 25984-63-8
Ethyl 2-(3-Cyano-4-Hydroxyphenyl)-4-Methyl-1,3-Thiazole-5-Carboxylate CAS 161798-02-3
Ethyl 2-(3-Cyano-4-Isobutoksyphenyl)-4-Methyl-5-Thiazolecarboxylate CAS 160844-75-7
Ethyl 2-(3-Formyl-4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylate CAS 161798-01-2
Ethyl 2-(3-Formyl-4-Isobutoksyphenyl)-4-Methylthiazole-5-Carboxylate CAS 161798-03-4
Ethyl 2-(4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylate CAS 161797-99-5
Navê Kîmyewî | Ethyl 2-(4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylate |
Sînonîm | Febuxostat Navîn |
Hejmara CAS | 161797-99-5 |
Hejmara CAT | RF-PI1122 |
Rewşa Stock | Li Stock, Kapasîteya Hilberînê 100 Ton / Sal |
Formula Molecular | C13H13NO3S |
Giraniya molekulî | 263,31 |
Melting Point | 180℃ |
Nîşan | Ruifu Chemical |
Şanî | Specifications |
Xuyabûnî | Powdera Zer Ronahî berbi Spî-Spî |
Nasname | Ji hêla HPLC ve;Ji hêla HNMR |
Windakirina li ser Drying | <0.50% |
Bermahî li ser Igition | <0.30% |
Nepaqijiya Yekane | <0.50% |
Tevahiya Nerazîbûnên | <1.00% |
Paqijî / Rêbaza Analîzê | >99.0% (ji hêla HPLC ve) |
Test Standard | Enterprise Standard |
Bikaranîna | Navbera Febuxostat (CAS: 144060-53-7) |
Pakêt: Şûşek, çenteyê pelê aluminum, 25kg / Drum karton, an li gorî hewcedariya xerîdar
Rewşa hilanînê:Di konteynerên girtî de li cîhek sar û zuwa hilînin;Ji ronahiyê û şilbûnê biparêzin
Ethyl 2-(4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylate (CAS: 161797-99-5) di senteza Febuxostat (CAS: 144060-53-7), xanthine oxidase/xanthine dehydrogenase de tê bikaranîn.Ji bo dermankirina hyperuricemia û goutê kronîk tê bikar anîn.40-120 mg/roj febuxostat di kêmkirina asta urate ya serum de bi bandor hate îsbat kirin dema ku ji bo birêvebirina hîperuricemia di nexweşên bi goutê de tê bikar anîn.Fabuxostat ji hêla Teijin Pharmaceuticals ve hate vedîtin û destûrnameya TAP Pharmaceuticals (ya ku niha beşek ji Takeda Pharmaceuticals e) hate wergirtin û li Dewletên Yekbûyî ji bo dermankirina hyperuricemia di nexweşên bi gout de hate pejirandin.